New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor ... (which recently completed Phase 1 clinica...)

New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor Properties

Date:10/24/2007

which recently completed Phase 1 clinical trials, RDEA119, a mitogen-activated ERK kinase (MEK) inhibitor for the treatment of cancer and inflammatory diseases, which has been cleared by the FDA to enter Phase 1 clinical trials, and a follow-on NNRTI and a follow-on MEK inhibitor, both of which are scheduled to enter first-in-human studies in the fourth quarter of 2007.

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding: Ardea's goals, including its goal of initiating a Phase 1 study of RDEA119 in patients with advanced cancer in the fourth quarter of 2007, evaluating RDEA119 for inflammatory diseases next year, and initiating clinical studies on three additional compounds this year, the expected properties and benefits of its compounds and the results of clinical and other studies. Risks that contribute to the uncertain nature of the forward-looking statements include: risks related to the outcomes of preclinical and clinical trials, risks related to regulatory approvals, delays in commencement of preclinical and clinical tests, and costs associated with internal development and in-licensing activities. These and other risks and uncertainties are described more fully in Ardea's most recently filed SEC documents, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, under the headings "Risk Factors." All forward-looking statements contained in this press release speak only as of the date on which they were made. Ardea undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related biology technology :

1. Blurb shows that print still captures imaginations
2. Kauffman study shows consistent entrepreneurial growth
3. Directory shows high-tech growth spurt in Dane Co.
4. Stem cell therapy shows visionary promise
5. TDS restates years of revenues, shows slight profit drop
6. As BIO shows mass of competition, hunt for partners is on
7. UW shows why avian flu hasnt spread among humans yet
8. NameProtect study shows 92% of top brands losing out on search engines
9. Stem cell breakthrough by UW shows why federal research should be broadened
10. Student survey shows surging demand for wireless access
11. Wisconsins tech employment shows increase, HR firm reports

Post Your Comments:

(Date:12/15/2009)... Epeius Biotechnologies Corporation, an emerging leader in the ... of the cutting-edge science behind its lead oncology ... world rediscovered the Cyclin G1 gene ... and disease progression, and thus a prime target ... National Cancer Institute investigating the role of microRNAs ...

(Date:12/15/2009)... -- Reportlinker.com announces that a new market ... ,, The Future of Orphan ... Pipeline Analysis and Reimbursement ,, ... Summary ,, The author has ... Orphan Diseases Therapeutics - Market Forecasts to ...

(Date:12/15/2009)... (NYSE: MOS ) plans to issue its ... tables on Tuesday, January 5, 2010, after the close ... Results will be available on Mosaic,s website at mosaicco.com/investors. ... call with presentation slides on Wednesday, January 6, 2010, ... at 11:00 a.m. Eastern Standard Time (10:00 a.m. Central ...

(Date:12/15/2009)... Thomson Reuters ... become the first drug pipeline database to fully ... This highly anticipated new content is being provided ... ,, Thomson Pharma will offer ... press releases, conferences, and other sources across all ...

[0] Scientists Rediscover Gene Target for Cancer Therapy [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement [0] Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call [0] Thomson Reuters is First to Offer Fully Integrated Pipeline and Clinical Trials

... Alfalight , a manufacturer of high-powered diode lasers, announced ... and development contract with the Air Force research laboratory ... the next 18 months, develop a multimode laser with ... current, and manufacturing variations. , ,This grant from the ...

... Madison, Wis. Since Hippocrates, born a few ... to symptoms of disease. Known as the Father of ... accurately describe disease symptoms. , ,Today, doctors still follow ... executive vice president and chief technology and medical officer ...

... been identified, search engines are leading the way for ... emerging related to the efficacy of these search engines, ... How soon and why could this happen? , ,If ... then todays search results, which often include a great ...

Other Biology Technology:Alfalight receives $3.8 million Air Force laser contract 2 Predictive medicine: Genes indicate diseases before symptoms do 2 When search engines collide 2 When search engines collide 3 When search engines collide 4

Alfalight receives $3.8 million Air Force laser contract Predictive medicine: Genes indicate diseases before symptoms do When search engines collide

(Date:12/15/2009)... has just signed an agreement with the British Society ... affiliation with the journal Biogerontology for an ... appoint one member of the Biogerontology editorial ... annually. Springer will sponsor the society and provide ... on www.springerlink.com . , Biogerontology ...

(Date:12/15/2009)... ., Despite the fact that physical space ... as to how space is encoded in their language. ... as ,left, right, front, back, to talk about spatial ... west, at all times for all scales: "The spoon ... snake by your Northern leg". Whether not only spatial ...

(Date:12/15/2009)... model organism, but there are currently few resources ... blood-forming tissues in this species. A newly ... from Cold Spring Harbor Laboratory Press fills this ... protocols for the preparation, enumeration, and microscopic examination ... tissues in the mouse. The laboratory manual ...

Breaking Biology News(10 mins):More than a jump to the left 2 New source of classical techniques for blood-based studies in the laboratory mouse 2 Governor Rendell 3A New State Investments Bear Fruit in Adams County 3B Help Pharmaceutical Company Expand in Philadelphia 6716 1 Governor Rendell 3A New State Investments Bear Fruit in Adams County 3B Help Pharmaceutical Company Expand in Philadelphia 6716 2 VirtualScopics Receives Issuance in Japan of Prominent Patent 6713 1 VirtualScopics Receives Issuance in Japan of Prominent Patent 6713 2 VirtualScopics Receives Issuance in Japan of Prominent Patent 6713 3 Green tea chemical combined with another may hold promise for treatment of brain disorders 62520 1 Green tea chemical combined with another may hold promise for treatment of brain disorders 62520 2

[0] Springer signs agreement with British Society of Research on Ageing [0] More than a jump to the left [0] New source of classical techniques for blood-based studies in the laboratory mouse

... an effective way to screen drugs against Huntington's disease ... most effective at keeping cells alive under conditions that ... , "These drugs have been tested in a ... trials and results are very difficult to interpret," said ...

... is a growing health problem. Giving antioxidants is recognised ... control their blood sugar levels. , The herbal ... marianum (silymarin) is known to have antioxidant properties and ... this extract can help people significantly lower the amount ...

... of a molecule he keeps in his office. He ... about the shape of a soy or corn protein, ... agricultural and biosystems engineering. Then he unfolded the model ... researchers add some glycerin ?a byproduct of biodiesel production ...

Other Biology News:Test reveals effectiveness of potential Huntington's disease drugs 2 Iowa State researchers improving plastics made from corn and soy proteins 2

Test reveals effectiveness of potential Huntington's disease drugs Herbal medicine silymarin may help sugar-control in people with type II diabetes Iowa State researchers improving plastics made from corn and soy proteins

... Slotted migration Chamber lid allows easy gel ... One-touch connectors for easy set up between power ... prevents current flow if the lid is removed ... and durability., Remote control can be ...

... ProFound Label Transfer Sulfo SBED Protein:Protein ... known as Label Transfer has rapidly gained ... protein interaction discovery. A growing number of ... Biotin Label Transfer Reagent to study a ...

... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...

... label transfer is fast emerging as a ... and confirmation. Until now, only amino groups ... label transfer reagents such as our Sulfo-SBED. ... Mts-Atf-LC-Biotin, are exciting additions to the protein ...

Biology Products:

Mini Horizontal Electrophoresis Unit i-MyRun.NC from Cosmo Bio Co., Ltd.ProFound Label Transfer Sulfo SBED Protein:Protein Interaction Reagent from Pierce Biotechnology, Inc.Incubator with Vortexing Shaker and Rotisserie from Major Science Mts-Atf-Biotin Label Transfer Reagent, 5 mg from Pierce Biotechnology, Inc.

New Oral MEK Inhibitor, RDEA119, Shows Favorable Anti-Tumor ...(which recently completed Phase 1 clinica...)